Pharmacia Corp. a future biotech powerhouse? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacia Corp. a future biotech powerhouse?

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jack Hartmann who wrote (12)	5/15/2000 6:49:00 PM
From: Jack Hartmann	Read Replies (2) of 35

Epimmune, Pharmacia Study Shows Promise In Animals Dow Jones Newswires SAN DIEGO -- Epimmune Inc. (EPMN) said the combination of its core vaccine technology with a novel drug called progenipoietin represents a promising new approach in immunotherapy for cancer. The novel progenipoietin-derived vaccine induces strong, disease-specific immune responses in an animal model, as reported by Epimmune scientists at the annual meeting of the American Association for Immunology in Seattle. The research represents the combined efforts of Epimmune and Pharmacia Corp. (PHA). Epimmune said the study examined the ability of progenipoietin-mobilized dendritic cells to present cytotoxic and helper T-cell epitopes. The results demonstrated that progenipoietin-mobilized dendritic cells are more potent at presenting helper T-cell epitopes than dendritic cells derived from bone marrow. "Dendritic cells have been shown to be effective at inducing anti-cancer T-cell responses in cancer patients, but are normally present in the blood and tissues in low numbers," Epimmune said in a press release Monday. -Michael Squires; Dow Jones Newswires; 201-938-5400 Epimmune said the study examined the ability of progenipoietin-mobilized dendritic cells to present cytotoxic and helper T-cell epitopes. The results demonstrated that progenipoietin-mobilized dendritic cells are more potent at presenting helper T-cell epitopes than dendritic cells derived from bone marrow. "Dendritic cells have been shown to be effective at inducing anti-cancer T-cell responses in cancer patients, but are normally present in the blood and tissues in low numbers," Epimmune said in a press release Monday. -Michael Squires; Dow Jones Newswires; 201-938-5400 ************* I don't think there has been one neative article on this company in the last month or so. Jack

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next